Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility.
The purpose of this study was to examine the effects of scopolamine on the physiological patterns occurring prior to and during motion sickness stimulation. In addition, the use of physiological profiles in the prediction of motion sickness was evaluated. Sixty subjects ingested either 0.6 mg scopolamine, 2.5 mg methscopolamine, or a placebo. Heart rate (HR), respiratory sinus arrhythmia (an index of vagal tone), and electrogastrograms were measured prior to and during the exposure to a rotating optokinetic drum. Compared to the other groups, the scopolamine group reported fewer motion sickness symptoms, and displayed lower HR, higher vagal tone, enhanced normal gastric myoelectric activity, and depressed gastric dysrhythmias before and during motion sickness induction. Distinct physiological profiles prior to drum rotation could reliably differentiate individuals who would develop gastric discomfort from those who would not. Symptom-free subjects were characterized by high levels of vagal tone and low HR across conditions, and by maintaining normal (3 cpm) electrogastrographic activity during drum rotation. It was concluded that scopolamine offered motion sickness protection by initiating a pattern of increased vagal tone and gastric myoelectric stability.
Uijtdehaage
S H
SH
Neuropsychiatric Institute, UCLA 90024-1759.
Stern
R M
RM
Koch
K L
KL
D000328:Adult; D000704:Analysis of Variance; D004341:Drug Evaluation; D004558:Electric Stimulation; D004562:Electrocardiography / Q000187:drug effects; D005583:Fourier Analysis; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009041:Motion Sickness / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D019832:N-Methylscopolamine; D010275:Parasympathetic Nervous System / Q000187:drug effects*; D010276:Parasympatholytics / Q000494:pharmacology*; D012399:Rotation / Q000009:adverse effects; D012601:Scopolamine / Q000494:pharmacology*; D012602:Scopolamine Derivatives / Q000494:pharmacology*; D014630:Vagus Nerve / Q000187:drug effects
D010276:Parasympatholytics; D012602:Scopolamine Derivatives; D012601:Scopolamine; D019832:N-Methylscopolamine